Key Insights
The Malabsorption Syndrome market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 12.10% from 2025 to 2033. This expansion is fueled by several key drivers. The rising prevalence of chronic diseases like Crohn's disease and celiac disease, which frequently lead to malabsorption, is a significant factor. Furthermore, advancements in diagnostic techniques and the development of novel therapeutic interventions, including targeted drug therapies and nutritional supplements, are contributing to market growth. Increased awareness among patients and healthcare professionals about malabsorption syndromes and their effective management further bolsters market expansion. The market segmentation reveals a significant contribution from GLP-1 receptor agonists and growth hormone therapies within the drug class category. Hospital pharmacies currently hold a substantial share of the distribution channel, reflecting the complexities of managing malabsorption often requiring in-patient care. However, the retail pharmacy segment is expected to grow, driven by increased access to specialized nutritional products and supportive care. Geographical analysis indicates strong market presence in North America and Europe, with developing economies in Asia-Pacific demonstrating significant growth potential as healthcare infrastructure improves and awareness campaigns gain traction.
Despite the promising outlook, the market faces certain restraints. High treatment costs associated with specialized medications and long-term management strategies can pose a barrier for some patients. Furthermore, the complexity of diagnosing malabsorption syndromes and the need for personalized treatment approaches can impact market penetration. Variations in healthcare reimbursement policies across different regions also represent a challenge. Nevertheless, continuous innovation in therapeutic options, coupled with a growing understanding of malabsorption syndromes, is expected to mitigate these challenges and sustain market expansion over the forecast period. The competitive landscape is characterized by both large pharmaceutical companies and specialized biotech firms, highlighting the diverse approaches and technological advancements shaping the future of malabsorption syndrome treatment.

Malabsorption Syndrome Industry Market Report: 2019-2033
This comprehensive report provides a detailed analysis of the Malabsorption Syndrome industry, encompassing market dynamics, growth trends, regional segmentation, product landscape, key players, and future outlook. The study period covers 2019-2033, with a focus on the base year 2025 and a forecast period of 2025-2033. The report leverages extensive data and insights to offer a valuable resource for industry professionals, investors, and researchers. The market size is projected to reach xx Million by 2033.
Malabsorption Syndrome Industry Market Dynamics & Structure
This section analyzes the market concentration, technological advancements, regulatory landscape, competitive dynamics, end-user demographics, and merger and acquisition (M&A) activities within the Malabsorption Syndrome treatment market. The industry is characterized by a moderately concentrated market structure, with several key players holding significant market share.
- Market Concentration: The top 5 companies account for approximately xx% of the global market share in 2025. This is expected to slightly decrease to xx% by 2033 due to increased competition from emerging players.
- Technological Innovation: Ongoing research and development in drug delivery systems and novel therapeutic agents are driving market growth. However, high R&D costs and stringent regulatory approvals pose significant barriers to innovation.
- Regulatory Frameworks: Stringent regulatory approvals for new therapies and varying reimbursement policies across different regions influence market dynamics. The approval of new treatments like teduglutide significantly impacts market growth.
- Competitive Product Substitutes: Limited effective substitutes for current therapies currently exist, creating a stable foundation for the market.
- End-User Demographics: The growing prevalence of conditions leading to malabsorption syndrome, such as Crohn's disease and short bowel syndrome, fuels market demand. The aging global population also contributes to the increasing incidence of these conditions.
- M&A Trends: The last 5 years have witnessed xx M&A deals in this sector, driven by the need to expand product portfolios and geographical reach. Strategic alliances and collaborations are also significant trends.
Malabsorption Syndrome Industry Growth Trends & Insights
The Malabsorption Syndrome market exhibits robust growth, driven by factors such as increasing prevalence of underlying conditions, advancements in treatment modalities, and rising healthcare expenditure. The market size is expected to experience a Compound Annual Growth Rate (CAGR) of xx% during the forecast period (2025-2033), expanding from xx Million in 2025 to xx Million in 2033. Market penetration rates for existing therapies vary across regions, with higher adoption observed in developed nations compared to emerging markets. Technological disruptions, such as the development of novel drug delivery systems, are expected to further accelerate market growth. Consumer behavior is shifting towards a preference for minimally invasive and effective treatments. Increased awareness and improved diagnosis of malabsorption syndrome are also significant contributors to market expansion.

Dominant Regions, Countries, or Segments in Malabsorption Syndrome Industry
North America currently holds the largest market share due to high healthcare expenditure, advanced healthcare infrastructure, and a substantial patient population. Europe follows closely. Within the drug class segment, GLP-1 and GLP-2 agonists lead in terms of market share and growth potential, owing to their efficacy and safety profiles. Hospital pharmacies remain the dominant distribution channel, reflecting the specialized nature of malabsorption syndrome treatments.
Key Drivers (North America):
- High healthcare expenditure
- Advanced healthcare infrastructure
- Strong research and development activities
- High prevalence of underlying diseases.
Key Drivers (Europe):
- Favorable reimbursement policies
- Growing awareness of malabsorption syndromes
- Increasing government initiatives to improve healthcare access
Segment Dominance:
- By Drug Class: GLP-1 and GLP-2 agonists dominate, followed by growth hormone and others.
- By Distribution Channel: Hospital pharmacies lead, followed by retail pharmacies and others.
Malabsorption Syndrome Industry Product Landscape
The Malabsorption Syndrome product landscape is characterized by a range of therapeutic agents, including GLP-1 and GLP-2 receptor agonists, growth hormone supplements, and other supportive therapies. These products are designed to address various aspects of malabsorption, such as nutrient absorption, gut motility, and overall patient well-being. Continuous innovation focuses on enhancing efficacy, improving drug delivery methods (such as subcutaneous injections), and minimizing side effects. The key selling propositions are improved efficacy, reduced side effects, and enhanced patient convenience. Technological advancements like targeted drug delivery systems and personalized medicine approaches are shaping future product development.
Key Drivers, Barriers & Challenges in Malabsorption Syndrome Industry
Key Drivers: The increasing prevalence of conditions such as Crohn’s disease and short bowel syndrome, coupled with rising healthcare expenditure and growing awareness, are primary growth drivers. Technological advancements in drug delivery and novel therapeutic agents further accelerate market growth. Favorable regulatory approvals for new therapies also contribute significantly.
Challenges: High R&D costs, stringent regulatory hurdles, and the need for specialized healthcare infrastructure pose significant challenges. Competition from existing and emerging therapies can also impact market growth. Furthermore, potential supply chain disruptions and varying reimbursement policies across regions create uncertainty for market players.
Emerging Opportunities in Malabsorption Syndrome Industry
Untapped markets in emerging economies offer significant growth opportunities. The development of innovative therapies targeting specific aspects of malabsorption syndrome presents substantial market potential. Personalized medicine approaches, leveraging genetic testing and other technologies to tailor treatments to individual patients, represent an exciting emerging trend. The focus on improving patient compliance through improved drug delivery systems and user-friendly formulations offers further opportunities.
Growth Accelerators in the Malabsorption Syndrome Industry Industry
Technological breakthroughs in drug development and delivery systems are expected to propel market expansion. Strategic partnerships and collaborations between pharmaceutical companies and research institutions facilitate innovation and accelerate the introduction of new treatments. Expansion into untapped markets and the development of effective patient education initiatives will further enhance market growth.
Key Players Shaping the Malabsorption Syndrome Industry Market
- OxThera Inc
- VectivBio AG
- Merck KGaA
- Nutrinia
- Nestle Health Science
- Ardelyx
- Takeda Pharmaceutical Company Limited
- Zealand Pharma
- Sancilio&Company Inc
- Hanmi Pharm Co Ltd
- OPKO Health Inc
- 9 Meters Biopharma
Notable Milestones in Malabsorption Syndrome Industry Sector
- June 2022: NICE recommends Takeda's Revestive (teduglutide) for Short Bowel Syndrome (SBS).
- October 2022: VectivBio releases positive interim data for apraglutide in a Phase 2 study for SBS.
In-Depth Malabsorption Syndrome Industry Market Outlook
The Malabsorption Syndrome market exhibits promising growth potential, driven by continuous innovation, increased prevalence of underlying diseases, and growing awareness. Strategic investments in R&D, coupled with expansion into new markets and the adoption of personalized medicine approaches, will significantly shape future market dynamics. Strategic partnerships and collaborations will play a crucial role in accelerating market growth. The market presents lucrative opportunities for both established players and emerging companies.
Malabsorption Syndrome Industry Segmentation
-
1. Drug Class
- 1.1. GLP-2
- 1.2. Growth Hormone
- 1.3. Glutamine
- 1.4. Others
-
2. Distribution Channel
- 2.1. Hospital Pharmacies
- 2.2. Retail Pharmacies
- 2.3. Others
Malabsorption Syndrome Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Rest of the World

Malabsorption Syndrome Industry REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 12.10% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1 Increased Prevalence of Short Bowel Syndrome and GI disorders such as volvulus
- 3.2.2 Inflammatory bowel disease (IBD)
- 3.2.3 Crohn's disease (CD) etc.; Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations
- 3.3. Market Restrains
- 3.3.1 Lack of Availability of the Approved Drugs in Developing Countries; Lethal Adverse Complications like Colonic Cancer
- 3.3.2 Polyps along with Common Side Effects Associated with the Medication
- 3.4. Market Trends
- 3.4.1. GLP-2 Drug Therapy is Expected to Hold a Significant Market Share Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. GLP-2
- 5.1.2. Growth Hormone
- 5.1.3. Glutamine
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.2.1. Hospital Pharmacies
- 5.2.2. Retail Pharmacies
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. North America Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 6.1.1. GLP-2
- 6.1.2. Growth Hormone
- 6.1.3. Glutamine
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 6.2.1. Hospital Pharmacies
- 6.2.2. Retail Pharmacies
- 6.2.3. Others
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 7. Europe Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 7.1.1. GLP-2
- 7.1.2. Growth Hormone
- 7.1.3. Glutamine
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 7.2.1. Hospital Pharmacies
- 7.2.2. Retail Pharmacies
- 7.2.3. Others
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 8. Asia Pacific Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 8.1.1. GLP-2
- 8.1.2. Growth Hormone
- 8.1.3. Glutamine
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 8.2.1. Hospital Pharmacies
- 8.2.2. Retail Pharmacies
- 8.2.3. Others
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 9. Rest of the World Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 9.1.1. GLP-2
- 9.1.2. Growth Hormone
- 9.1.3. Glutamine
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 9.2.1. Hospital Pharmacies
- 9.2.2. Retail Pharmacies
- 9.2.3. Others
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 10. North America Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.1.1 United States
- 10.1.2 Canada
- 10.1.3 Mexico
- 11. Europe Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1 Germany
- 11.1.2 United Kingdom
- 11.1.3 France
- 11.1.4 Spain
- 11.1.5 Italy
- 11.1.6 Spain
- 11.1.7 Belgium
- 11.1.8 Netherland
- 11.1.9 Nordics
- 11.1.10 Rest of Europe
- 12. Asia Pacific Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1 China
- 12.1.2 Japan
- 12.1.3 India
- 12.1.4 South Korea
- 12.1.5 Southeast Asia
- 12.1.6 Australia
- 12.1.7 Indonesia
- 12.1.8 Phillipes
- 12.1.9 Singapore
- 12.1.10 Thailandc
- 12.1.11 Rest of Asia Pacific
- 13. South America Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1 Brazil
- 13.1.2 Argentina
- 13.1.3 Peru
- 13.1.4 Chile
- 13.1.5 Colombia
- 13.1.6 Ecuador
- 13.1.7 Venezuela
- 13.1.8 Rest of South America
- 14. North America Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1 United States
- 14.1.2 Canada
- 14.1.3 Mexico
- 15. MEA Malabsorption Syndrome Industry Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1 United Arab Emirates
- 15.1.2 Saudi Arabia
- 15.1.3 South Africa
- 15.1.4 Rest of Middle East and Africa
- 16. Competitive Analysis
- 16.1. Global Market Share Analysis 2024
- 16.2. Company Profiles
- 16.2.1 OxThera Inc
- 16.2.1.1. Overview
- 16.2.1.2. Products
- 16.2.1.3. SWOT Analysis
- 16.2.1.4. Recent Developments
- 16.2.1.5. Financials (Based on Availability)
- 16.2.2 VectivBio AG
- 16.2.2.1. Overview
- 16.2.2.2. Products
- 16.2.2.3. SWOT Analysis
- 16.2.2.4. Recent Developments
- 16.2.2.5. Financials (Based on Availability)
- 16.2.3 Merck KGaA
- 16.2.3.1. Overview
- 16.2.3.2. Products
- 16.2.3.3. SWOT Analysis
- 16.2.3.4. Recent Developments
- 16.2.3.5. Financials (Based on Availability)
- 16.2.4 Nutrinia
- 16.2.4.1. Overview
- 16.2.4.2. Products
- 16.2.4.3. SWOT Analysis
- 16.2.4.4. Recent Developments
- 16.2.4.5. Financials (Based on Availability)
- 16.2.5 Nestle Health Science
- 16.2.5.1. Overview
- 16.2.5.2. Products
- 16.2.5.3. SWOT Analysis
- 16.2.5.4. Recent Developments
- 16.2.5.5. Financials (Based on Availability)
- 16.2.6 Ardelyx
- 16.2.6.1. Overview
- 16.2.6.2. Products
- 16.2.6.3. SWOT Analysis
- 16.2.6.4. Recent Developments
- 16.2.6.5. Financials (Based on Availability)
- 16.2.7 Takeda Pharmaceutical Company Limited
- 16.2.7.1. Overview
- 16.2.7.2. Products
- 16.2.7.3. SWOT Analysis
- 16.2.7.4. Recent Developments
- 16.2.7.5. Financials (Based on Availability)
- 16.2.8 Zealand Pharma
- 16.2.8.1. Overview
- 16.2.8.2. Products
- 16.2.8.3. SWOT Analysis
- 16.2.8.4. Recent Developments
- 16.2.8.5. Financials (Based on Availability)
- 16.2.9 Sancilio&Company Inc
- 16.2.9.1. Overview
- 16.2.9.2. Products
- 16.2.9.3. SWOT Analysis
- 16.2.9.4. Recent Developments
- 16.2.9.5. Financials (Based on Availability)
- 16.2.10 Hanmi Pharm Co Ltd
- 16.2.10.1. Overview
- 16.2.10.2. Products
- 16.2.10.3. SWOT Analysis
- 16.2.10.4. Recent Developments
- 16.2.10.5. Financials (Based on Availability)
- 16.2.11 OPKO Health Inc
- 16.2.11.1. Overview
- 16.2.11.2. Products
- 16.2.11.3. SWOT Analysis
- 16.2.11.4. Recent Developments
- 16.2.11.5. Financials (Based on Availability)
- 16.2.12 9 Meters Biopharma
- 16.2.12.1. Overview
- 16.2.12.2. Products
- 16.2.12.3. SWOT Analysis
- 16.2.12.4. Recent Developments
- 16.2.12.5. Financials (Based on Availability)
- 16.2.1 OxThera Inc
List of Figures
- Figure 1: Global Malabsorption Syndrome Industry Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: Global Malabsorption Syndrome Industry Volume Breakdown (K Unit, %) by Region 2024 & 2032
- Figure 3: North America Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 4: North America Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 5: North America Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 6: North America Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 7: Europe Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 8: Europe Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 9: Europe Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 10: Europe Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 11: Asia Pacific Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 12: Asia Pacific Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 13: Asia Pacific Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 14: Asia Pacific Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 15: South America Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 16: South America Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 17: South America Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 18: South America Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 19: North America Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 20: North America Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 21: North America Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 22: North America Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 23: MEA Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 24: MEA Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 25: MEA Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 26: MEA Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 27: North America Malabsorption Syndrome Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 28: North America Malabsorption Syndrome Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 29: North America Malabsorption Syndrome Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 30: North America Malabsorption Syndrome Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 31: North America Malabsorption Syndrome Industry Revenue (Million), by Distribution Channel 2024 & 2032
- Figure 32: North America Malabsorption Syndrome Industry Volume (K Unit), by Distribution Channel 2024 & 2032
- Figure 33: North America Malabsorption Syndrome Industry Revenue Share (%), by Distribution Channel 2024 & 2032
- Figure 34: North America Malabsorption Syndrome Industry Volume Share (%), by Distribution Channel 2024 & 2032
- Figure 35: North America Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 36: North America Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 37: North America Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 38: North America Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 39: Europe Malabsorption Syndrome Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 40: Europe Malabsorption Syndrome Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 41: Europe Malabsorption Syndrome Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 42: Europe Malabsorption Syndrome Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 43: Europe Malabsorption Syndrome Industry Revenue (Million), by Distribution Channel 2024 & 2032
- Figure 44: Europe Malabsorption Syndrome Industry Volume (K Unit), by Distribution Channel 2024 & 2032
- Figure 45: Europe Malabsorption Syndrome Industry Revenue Share (%), by Distribution Channel 2024 & 2032
- Figure 46: Europe Malabsorption Syndrome Industry Volume Share (%), by Distribution Channel 2024 & 2032
- Figure 47: Europe Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 48: Europe Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 49: Europe Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 50: Europe Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 51: Asia Pacific Malabsorption Syndrome Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 52: Asia Pacific Malabsorption Syndrome Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 53: Asia Pacific Malabsorption Syndrome Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 54: Asia Pacific Malabsorption Syndrome Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 55: Asia Pacific Malabsorption Syndrome Industry Revenue (Million), by Distribution Channel 2024 & 2032
- Figure 56: Asia Pacific Malabsorption Syndrome Industry Volume (K Unit), by Distribution Channel 2024 & 2032
- Figure 57: Asia Pacific Malabsorption Syndrome Industry Revenue Share (%), by Distribution Channel 2024 & 2032
- Figure 58: Asia Pacific Malabsorption Syndrome Industry Volume Share (%), by Distribution Channel 2024 & 2032
- Figure 59: Asia Pacific Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 60: Asia Pacific Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 61: Asia Pacific Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 62: Asia Pacific Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
- Figure 63: Rest of the World Malabsorption Syndrome Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 64: Rest of the World Malabsorption Syndrome Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 65: Rest of the World Malabsorption Syndrome Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 66: Rest of the World Malabsorption Syndrome Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 67: Rest of the World Malabsorption Syndrome Industry Revenue (Million), by Distribution Channel 2024 & 2032
- Figure 68: Rest of the World Malabsorption Syndrome Industry Volume (K Unit), by Distribution Channel 2024 & 2032
- Figure 69: Rest of the World Malabsorption Syndrome Industry Revenue Share (%), by Distribution Channel 2024 & 2032
- Figure 70: Rest of the World Malabsorption Syndrome Industry Volume Share (%), by Distribution Channel 2024 & 2032
- Figure 71: Rest of the World Malabsorption Syndrome Industry Revenue (Million), by Country 2024 & 2032
- Figure 72: Rest of the World Malabsorption Syndrome Industry Volume (K Unit), by Country 2024 & 2032
- Figure 73: Rest of the World Malabsorption Syndrome Industry Revenue Share (%), by Country 2024 & 2032
- Figure 74: Rest of the World Malabsorption Syndrome Industry Volume Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Region 2019 & 2032
- Table 3: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 4: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 5: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Distribution Channel 2019 & 2032
- Table 6: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Distribution Channel 2019 & 2032
- Table 7: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 8: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Region 2019 & 2032
- Table 9: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 11: United States Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: United States Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 13: Canada Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Canada Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 15: Mexico Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Mexico Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 17: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 18: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 19: Germany Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: Germany Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 21: United Kingdom Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: United Kingdom Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 23: France Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 24: France Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 25: Spain Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Spain Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 27: Italy Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Italy Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 29: Spain Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: Spain Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 31: Belgium Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 32: Belgium Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 33: Netherland Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 34: Netherland Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 35: Nordics Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 36: Nordics Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 37: Rest of Europe Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: Rest of Europe Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 39: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 40: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 41: China Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: China Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 43: Japan Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Japan Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 45: India Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: India Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 47: South Korea Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: South Korea Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 49: Southeast Asia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 50: Southeast Asia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 51: Australia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 52: Australia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 53: Indonesia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 54: Indonesia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 55: Phillipes Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 56: Phillipes Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 57: Singapore Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 58: Singapore Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 59: Thailandc Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 60: Thailandc Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 61: Rest of Asia Pacific Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 62: Rest of Asia Pacific Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 63: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 64: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 65: Brazil Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 66: Brazil Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 67: Argentina Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 68: Argentina Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 69: Peru Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 70: Peru Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 71: Chile Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 72: Chile Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 73: Colombia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 74: Colombia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 75: Ecuador Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 76: Ecuador Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 77: Venezuela Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 78: Venezuela Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 79: Rest of South America Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 80: Rest of South America Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 81: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 82: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 83: United States Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 84: United States Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 85: Canada Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 86: Canada Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 87: Mexico Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 88: Mexico Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 89: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 90: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 91: United Arab Emirates Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 92: United Arab Emirates Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 93: Saudi Arabia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 94: Saudi Arabia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 95: South Africa Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 96: South Africa Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 97: Rest of Middle East and Africa Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 98: Rest of Middle East and Africa Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 99: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 100: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 101: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Distribution Channel 2019 & 2032
- Table 102: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Distribution Channel 2019 & 2032
- Table 103: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 104: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 105: United States Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 106: United States Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 107: Canada Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 108: Canada Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 109: Mexico Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 110: Mexico Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 111: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 112: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 113: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Distribution Channel 2019 & 2032
- Table 114: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Distribution Channel 2019 & 2032
- Table 115: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 116: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 117: Germany Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 118: Germany Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 119: United Kingdom Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 120: United Kingdom Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 121: France Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 122: France Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 123: Italy Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 124: Italy Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 125: Spain Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 126: Spain Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 127: Rest of Europe Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 128: Rest of Europe Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 129: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 130: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 131: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Distribution Channel 2019 & 2032
- Table 132: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Distribution Channel 2019 & 2032
- Table 133: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 134: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 135: China Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 136: China Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 137: Japan Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 138: Japan Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 139: India Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 140: India Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 141: Australia Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 142: Australia Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 143: South Korea Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 144: South Korea Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 145: Rest of Asia Pacific Malabsorption Syndrome Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 146: Rest of Asia Pacific Malabsorption Syndrome Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 147: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 148: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 149: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Distribution Channel 2019 & 2032
- Table 150: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Distribution Channel 2019 & 2032
- Table 151: Global Malabsorption Syndrome Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 152: Global Malabsorption Syndrome Industry Volume K Unit Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Malabsorption Syndrome Industry?
The projected CAGR is approximately 12.10%.
2. Which companies are prominent players in the Malabsorption Syndrome Industry?
Key companies in the market include OxThera Inc, VectivBio AG, Merck KGaA, Nutrinia, Nestle Health Science, Ardelyx, Takeda Pharmaceutical Company Limited, Zealand Pharma, Sancilio&Company Inc, Hanmi Pharm Co Ltd, OPKO Health Inc , 9 Meters Biopharma.
3. What are the main segments of the Malabsorption Syndrome Industry?
The market segments include Drug Class, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD XX Million as of 2022.
5. What are some drivers contributing to market growth?
Increased Prevalence of Short Bowel Syndrome and GI disorders such as volvulus. Inflammatory bowel disease (IBD). Crohn's disease (CD) etc.; Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations.
6. What are the notable trends driving market growth?
GLP-2 Drug Therapy is Expected to Hold a Significant Market Share Over the Forecast Period.
7. Are there any restraints impacting market growth?
Lack of Availability of the Approved Drugs in Developing Countries; Lethal Adverse Complications like Colonic Cancer. Polyps along with Common Side Effects Associated with the Medication.
8. Can you provide examples of recent developments in the market?
In October 2022, VectivBio Holding AG released positive interim data from the company's ongoing Phase 2 study evaluating the safety, pharmacokinetics, and efficacy of apraglutide, a GLP-2 agonist, in adult patients with Short Bowel Syndrome.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Malabsorption Syndrome Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Malabsorption Syndrome Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Malabsorption Syndrome Industry?
To stay informed about further developments, trends, and reports in the Malabsorption Syndrome Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence